opc 12759 has been researched along with Vitiligo in 1 studies
rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase
Vitiligo: A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feily, A | 1 |
| Rasaii, S | 1 |
| Nilforoushzadeh, MA | 1 |
1 other study available for opc 12759 and Vitiligo
| Article | Year |
|---|---|
Rebamipide as a novel addition to the antivitiligo ordnance.
Topics: Alanine; Antioxidants; Cytokines; Humans; Oxidative Stress; Quinolones; Vitiligo | 2015 |